Incannex announces positive results from phase 2 clinical trial investigating the effect of ihl-42x for treatment of obstructive sleep apnoea

Highlights: ihl-42x reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed low dose ihl-42x exhibited superior safety and efficacy metrics to mid and high doses low dose ihl-42x reduced ahi by an average of 50.7% compared to baseline with 25% of participants experiencing a reduction in the apnoea hypopnea index of greater that 80% oxygen desaturation index was reduced by 59.7% relative to baseline while taking low dose ihl-42x, improving sleep quality and reducing cardiovascular stress in low dose ihl-42x samples, thc concentrations in blood were well below the limits for impaired driving the morning after dose administration ihl-42x was well tolerated – low dose ihl-42x was observed to have a lower number of total treatment emergent adverse events than placebo low dose ihl-42x reduced ahi substantially more effectively than is reported for the component active pharmaceutical ingredients, dronabinol and acetazolamide, as unregistered monotherapies. melbourne, australia , june 3, 2022 /prnewswire/ -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), ('incannex' or the 'company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed analysis of data from the phase 2 proof-of-concept clinical trial investigating ihl-42x for treatment of obstructive sleep apnoea ('osa').
IXHL Ratings Summary
IXHL Quant Ranking